AbbVie is trading 3.1% down at $255.21 as investors position ahead of its Q2 2026 earnings report scheduled for July 31, 2026.
- The price action suggests short-term caution rather than a clear change in fundamentals, as the stock currently trades near average analyst targets.
- Market sentiment remains generally positive regarding the company's key growth drivers, Skyrizi and Rinvoq.